We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-7.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.41B
AUM Growth
-$143M
Cap. Flow
+$78.9M
Cap. Flow %
5.61%
Top 10 Hldgs %
48.2%
Holding
246
New
54
Increased
32
Reduced
53
Closed
52

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$38M
2
FOLD
Amicus Therapeutics
FOLD
+$22M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$21.2M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.7M
5
ANIP icon
ANI Pharmaceuticals
ANIP
+$15.6M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$25.1M
2
DXCM icon
DexCom
DXCM
+$15.7M
3
AERI
Aerie Pharmaceuticals
AERI
+$13.5M
4
ASRT
Assertio
ASRT
+$13.4M
5
CRBP icon
Corbus Pharmaceuticals
CRBP
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.84%
2 Miscellaneous 1.6%
3 Consumer Staples 0.43%
4 Consumer Discretionary 0.07%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
A icon
176
Agilent Technologies
A
$42.4B
– –
-10,540
Closed -$496K
ACAD icon
177
Acadia Pharmaceuticals
ACAD
$4.61B
– –
-65,240
Closed -$1.73M
AMRN
178
Amarin Corp
AMRN
$294M
– –
-81,114
Closed -$5.17M
APYX icon
179
Apyx Medical
APYX
$125M
– –
-48,544
Closed -$253K
ARAY icon
180
Accuray
ARAY
$27.5M
– –
-27,300
Closed -$174K
ASRT
181
DELISTED
Assertio
ASRT
– –
-8,917
Closed -$13.4M
BRKR icon
182
Bruker
BRKR
$8.49B
$0 ﹤0.01%
+3
New +$66
BSX icon
183
Boston Scientific
BSX
$63.6B
$0 ﹤0.01%
+3
New +$65
CAH icon
184
Cardinal Health
CAH
$54.1B
– –
-6,398
Closed -$497K
CLLS
185
Cellectis
CLLS
$162M
– –
-179,506
Closed -$4.32M
COR icon
186
Cencora
COR
$61.7B
– –
-6,500
Closed -$525K
CRL icon
187
Charles River Laboratories
CRL
$13B
– –
-5,482
Closed -$457K
DHR icon
188
Danaher
DHR
$147B
$0 ﹤0.01%
+3
New +$208
DVA icon
189
DaVita
DVA
$12.2B
$0 ﹤0.01%
+3
New +$187
DVAX
190
PUT
DELISTED
Dynavax Technologies
DVAX
– –
-16,000
Closed -$7.18M
DXCM icon
191
DexCom
DXCM
$32.6B
– –
-715,396
Closed -$15.7M
ELV icon
192
Elevance Health
ELV
$90.6B
– –
-3,400
Closed -$426K
GLD icon
193
SPDR Gold Trust
GLD
$145B
$0 ﹤0.01%
+1
New +$116
HCA icon
194
HCA Healthcare
HCA
$91.8B
– –
-6,202
Closed -$469K
IQV icon
195
IQVIA
IQV
$44.4B
– –
-5,103
Closed -$414K
ISRG icon
196
Intuitive Surgical
ISRG
$133B
– –
-1,800
Closed -$145K
IVV icon
197
iShares Core S&P 500 ETF
IVV
$837B
$0 ﹤0.01%
+1
New +$220
IWS icon
198
iShares Russell Mid-Cap Value ETF
IWS
$15.2B
$0 ﹤0.01%
+2
New +$156
JNJ icon
199
Johnson & Johnson
JNJ
$644B
$0 ﹤0.01%
+2
New +$231
LH icon
200
Labcorp
LH
$26.3B
– –
-4,644
Closed -$549K
6 7
8
9 10

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Perceptive Advisors held 246 positions worth $1.41B, down 9.2% from $1.55B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $78.9M of net new capital in Q4 2016, opening 54 new positions and adding to 32 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $25.1M trimmed.

  • Perceptive Advisors's largest Q4 2016 buy was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q4 2016, an estimated $38M increase.
  • Perceptive Advisors's biggest Q4 2016 reduction was Sarepta Therapeutics, cutting an estimated $25.1M.
  • Perceptive Advisors fully exited DexCom in Q4 2016, selling an estimated $15.7M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.41B portfolio in Q4 2016.
  • Perceptive Advisors opened 54 new positions and closed 52 in Q4 2016.
  • Perceptive Advisors's portfolio value fell 9.2% quarter-over-quarter to $1.41B.

Based on Perceptive Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.